Updated October 10, 2018 07:51:28Lupin Pharmaceuticals announced in September that it had entered into a definitive agreement to acquire the rights to a variety of brands including Azurea and Azurean, as well as an undisclosed number of branded pharmaceuticals.
However, the deal still does not provide for a definitive sales revenue agreement between the two companies.
The new agreement was announced on September 23, and the company had previously confirmed that it would continue to develop and sell generic versions of the drug.
In a statement, Lupin said that it intends to enter into the new agreement “at a timely and reasonable time.”
In addition to the two brands acquired, the agreement also includes a $1 billion fund, and is subject to regulatory approval.
The deal includes two major milestones: the first will be to acquire a total of approximately $8 billion in marketable assets, and another $1.6 billion in non-marketable assets.
The company also expects to invest a total amount of $1,500 million in its international expansion program, and to invest another $2.5 billion in the global pharma business.
Lupins shares closed at $37.93 on the New York Stock Exchange, and are currently trading at $42.28.LUPINPHARMACEUTICALS’ NEW SALES AGREEMENTSLupis pharmaceuticals is set to complete the acquisition of Azureas brand in 2019, and in 2020, Azure’s brand will be acquired by inovio.
In the third quarter of 2019, Lupins sales rose $3.3 million to $5.45 billion, an increase of 14 percent over the previous quarter, according to the company’s financial statements.
The following year, the company expects to achieve $1bn in sales growth with a total net sales gain of $3 billion.
In addition, the number of product introductions will increase to over 500 by 2020, according the company.
Lipin is also expected to sell an additional 2,600 generic drugs in 2020.LUpins shares are trading at about $42 a share, which is above the market cap of the company, and up about 25 percent from the closing price on September 24, 2018, which was $42 on the Nasdaq.
Luppi Pharmaceuticals is also set to sell Azure products, and expects to continue to grow sales through 2020, although it expects the company to generate revenue losses of $2 billion.
Lofa Pharmaceuticals also plans to acquire Azure, but is not expected to enter a definitive deal with Lupins.LUNA Pharma is set in to acquire all of Azura’s branded products, including Azures products, as part of the deal.
Luna is set for a net sales increase of $5 billion during the 2021 fiscal year, which includes the purchase of Azuras brands and brand-branded generic drugs.
In addition, Nuance Pharma is slated to purchase Azure brands for the first time.
Nuance is expected to invest $2bn in its expansion efforts, and has plans to expand its drug portfolio to encompass generic drugs, as opposed to Azure.
Liu-Hsiung Hsu, MD, and Andrew Huang, MD are with Lazard Capital Advisors in Shanghai.